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Abstract 
Objective: Medication non-adherence following acute coronary syndrome (ACS) is associated with poor 
clinical outcomes. A systematic review and meta-analysis were undertaken to identify psychosocial 
factors associated with medication adherence in patients with ACS.  
Methods: A search of electronic databases (Cochrane Library, Medline, EMBASE, PsycINFO, Web of 
Science, International Pharmaceutical Abstracts, CINAHL, ASSIA, OpenGrey, EthOS and WorldCat) was 
undertaken to identify relevant articles published in English between 2000 and 2014. Articles were 
screened against our inclusion criteria and data on study design, sample characteristics, predictors, 
outcomes, analyses, key findings and study limitations were abstracted.  
Results: Our search identified 3609 records, of which 17 articles met our inclusion criteria (15 
independent studies). Eight out of ten studies found an association between depression and non-
adherence. A meta-analysis revealed that depressed patients were twice as likely to be non-adherent 
compared to patients without depression (OR = 2.00, 95% CI 1.57-3.33, p = .015). Type D personality was 
found to predict non-adherence in both studies in which it was measured. Three out of three studies 
reported that treatment beliefs based on the Necessity-Concerns Framework predicted medication non-
adherence and there was some evidence that social support was associated with better adherence. 
There was insufficient data to meta-analyse all other psychosocial factors identified. 
Conclusion: There was some evidence that psychosocial factors, particularly depression, were 
associated with medication adherence following ACS. Targeting depressive symptoms, screening for 
Type D personality, challenging maladaptive treatment beliefs, and providing better social support for 
patients may be useful strategies to improve medication adherence. 
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1. Introduction 
1.1 Background 
Acute coronary syndrome (ACS) presents a significant burden for healthcare providers with annual 
estimates for the number of hospitalisations totalling 175,000 and 595,000 in the UK and US respectively 
[1,2]. Following ACS, patients are often discharged from hospital with a number of cardiac medications. 
Despite their therapeutic benefit when used appropriately, many patients do not persist or adhere to 
the regimen prescribed to them [3,4].   
A large meta-analysis estimated that approximately one third of patients were non-adherent to 
medication after a cardiac event, irrespective of the type of cardiac drug prescribed [5]. A retrospective 
analysis of 4591 patients with acute myocardial infarction (AMI) found more than 25% had not filled 
their cardiac medications after 1 week and 20% had still not filled their prescriptions at 4 months post-
discharge [6]. Furthermore, a large prospective study of 13,830 patients with ACS found that 20% were 
non-adherent to angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers 
(ARBs) 6 months after hospital discharge [7].  
In addition to medication non-adherence being highly prevalent, it also predicts poor clinical outcomes 
in cardiac patients. Suboptimal medication adherence is associated with increased morbidity [8,9,10], 
mortality [9,11,12], and healthcare cost [8]. Ho [11] found that patients with AMI that discontinued 
aspirin, β-blocker, and statin within 1 month were 3.8 times more likely to have died by 12 months 
compared to patients that continued with one or more of the medications. 
1.2 Predictors of medication adherence 
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Most of the research to date has focused on sociodemographic and disease-related factors such as age 
[6,9,12-16], gender [7,12,14,17,18], and disease comorbidity [9,13,16,19-21]. A recent review by Chen et 
al. (2015) [22] investigated predictors of medication adherence following ACS and found a lack evidence 
for these types of factors in predicting adherence. While it is useful to understand how 
sociodemographic and disease-related factors affect medication adherence, they are generally not 
amenable to change [22,23]. There is growing interest into how psychosocial factors - cognitive-related, 
mood-related and social-contextual factors - influence medication adherence, particularly around 
factors that have the potential to be modified through intervention [3,24]. 
Cognitive-related factors such as beliefs, perceptions and attitudes towards cardiac treatment may 
influence medication adherence [25,26]. Previous studies have shown that patient beliefs about 
medications predicted adherence in other cardiac patient populations including coronary heart disease 
(CHD) [27], heart failure [28], and hypertension [29]. It is not yet fully understood how beliefs about 
treatment along with other cognitions affect health behaviour following acute cardiac events. 
Mood-related factors such as depression may also affect medication adherence in cardiac patients 
[30,31]. Depression has been shown to predict treatment non-adherence in patients with CHD [32-38]. 
In acute cardiac patients, the rate of depression is high (7-31%) [39] and is associated with poor clinical 
outcomes [40], which may in part be attributed to suboptimal medication adherence. 
Other psychosocial factors relating to a patient’s social context such as levels of social support may also 
contribute to medication adherence [41,42]. Understanding a patient’s social situation is important in 
order to decide which treatments are most appropriate and to identify any barriers that may affect 
treatment adherence [43,44]. 
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Due to the complex nature of medication adherence, it is likely that many factors contribute and overlap 
with one another. To our knowledge, there are no reviews of the literature pertaining to psychosocial 
factors in medication non-adherence following ACS. 
1.3 Objectives 
The aim of this systematic review was to identify psychosocial factors associated with medication non-
adherence following ACS and to use meta-analysis to determine the strength of such effects. 
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2. Methodology 
The present study is reported in accordance of both Preferred Reporting Items for Systematic reviews 
and Meta-Analysis (PRISMA) [45] and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) 
[46] guidelines.  
2.1 Search strategy 
A search of electronic databases was undertaken in March 2015 that included the Cochrane Library, 
Medline, EMBASE, PsycINFO, Web of Science, International Pharmaceutical Abstracts, Cumulative Index 
to Nursing and Allied Health Literature (CINAHL) and Applied Social Sciences Index and Abstracts (ASSIA). 
An additional online search of three electronic databases - OpenGrey, EthOS and WorldCat – Thesis and 
Dissertations - was done to identify relevant unpublished and grey literature (work not published in 
peer-reviewed books and journals). 
Our search was limited to English language articles published between 2000 and 2014. The decision to 
use this search period was based on the publication of the landmark Clopidogrel in Unstable Angina to 
Prevent Recurrent Events (CURE) trial in 2001 which found dual antiplatelet therapy (DAPT) consisting of 
clopidogrel paired with aspirin to be clinically effective in patients with coronary artery disease (CAD) 
[47]. Since the CURE trial, DAPT has been considered a key therapeutic regimen for secondary cardiac 
prevention [48-52] and it was expected our search would capture studies using the latest cardiac 
medication prescribing guidelines based on CURE. In addition, limiting the studies to those published in 
the last 15 years may assist the review to be more relevant to current clinical practice, as there have 
been many additional drugs and refinements in regimens in the last decade or two that have been 
shown to enhance outcome. 
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Our search terms were comprised of three themes: i) disease-related terms (i.e., “acute coronary 
syndrome”, “myocardial infarction”, “unstable angina”); ii) medication-related terms (i.e., “antiplatelet 
therapy”, “aspirin”, “statin”), and; iii) adherence-related terms (i.e., “adherence”, “persistence”, 
“compliance”) (see Appendix I for full search strategy). Independently sourced articles outside of the 
search results were identified through manually screening reference lists of relevant articles.  
2.2 Inclusion criteria 
The inclusion criteria were based on the Participants, Interventions, Comparator, Outcomes, and Setting 
(PICOS) approach in the PRISMA guidance [45]. We defined psychosocial predictors as variables that 
relate to the influence of social factors on an individual’s mind or behaviour and to the interrelation of 
behavioural and social factors [53]. Examples of psychosocial factors included: i) cognitive-related: 
beliefs, perceptions, attitudes, self-efficacy, coping style, ii) mood-related: mood state, perceived 
stress/stressors, iii) and social contextual: social influences, social support. Studies were included if they 
met the following criteria:  
i) Adult patients with ACS (diagnoses of myocardial infarction (MI) and/or unstable angina) 
over 18 years of age. 
ii) Cross-sectional, retrospective cohort or prospective cohort studies. 
iii) Measured adherence (both validated/non-validated methods) to cardiac medications 
including: antiplatelet agents (aspirin, thienopyridines, DAPT), ACE inhibitors, ARBs, β-
blockers or lipid-lowering agents (i.e., statins), calcium channel blockers or diuretics (for 
treatment of cardiac disease only). 
iv) Included a standardized measurement of a psychosocial variable. 
v) Assessed the strength of association between the psychosocial factor and adherence. 
vi) Articles published in English between 2000 and 2014. 
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Studies were excluded if they met the following criteria: 
i) Primary prevention of ACS. 
ii) Patients under 18 years. 
iii) No measure of medication adherence. 
iv) Focused solely on non-psychosocial variables such as sociodemographic and clinical factors. 
v) Articles published pre-2000 and not in English. 
2.3 Data collection 
Electronic database searches were undertaken by the lead researcher (JC) who used bibliographic 
software to manage the search results. After duplicates were removed, the remaining articles were 
screened manually by title and abstract using the inclusion criteria detailed above. Relevant full-text 
articles were obtained and their eligibility evaluated by the lead researcher. Co-authors (VA and JW) 
were given a sample of 40 relevant articles that met or almost met the inclusion criteria in order to 
validate the search process. Any reviewer disagreements were settled by consensus, although interrater 
reliability was very high. Using a standardised form, information was abstracted for study country, study 
design, study setting, sample characteristics, sample size, medication class studied, adherence 
measures, follow up period, psychosocial predictors, predictor measure, main analyses, key findings and 
study limitations. Authors were contacted if additional information to determine eligibility was required. 
We contacted three authors for further information which was provided in each case. 
2.4 Quality Assessment 
To assess study quality, we used an adaptation of the Quality In Prognosis Studies (QUIPS) tool that was 
developed to identify the risk of bias in studies of prognostic factors [54]. The original QUIPS tool 
comprises six domains of bias: i) study participation; ii) study attrition; iii) prognostic factor 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
9 
 
measurement; iv) outcome measurement; v) confounding measurement and; vi) statistical analyses. 
Oosterom-Calo et al. [55] adapted the QUIPS tool to include questions (17-items) rather than 
statements, with each item scored between 1 and 3. Based on an average score across all questions, 
studies were classified as ‘poor’, ‘fair’ or ‘good’ quality. The adapted QUIPS tool has been used to assess 
study quality in two recent systematic reviews of medicine adherence in heart failure [55,56]. 
2.5 Statistical Analysis 
Where appropriate, direction of effect was manipulated for consistent reporting (i.e., showing 
associations between predictors and non-adherence rather than adherence). Where there were 
sufficient data, the overall effect of each predictor of adherence was pooled using a random effects 
method for meta-analysis. The most common effect size metric reported were odds ratios. Where 
another effect size was reported (e.g., standardised mean difference) this was converted to the odds 
ratio metric [57]. Adjusted effect size estimates were used where available. The I2 statistic was used to 
estimate statistical heterogeneity and potential publication bias was determined using funnel plots and 
Egger’s test for small study effects. All analyses were done using Stata 14.1 statistics software package. 
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3. Results 
3.1 Selection process 
An online database search of published work identified 5653 records (see Figure 1). A search of 
unpublished and grey literature identified 35 records and a further 19 records were independently 
sourced using reference lists of relevant papers. After removing 2098 duplicates, the remaining 3609 
records were screened based on their title and abstract. A total of 3316 records were excluded leaving 
292 articles for full-text screening. Seventeen studies [58-74] met the inclusion criteria and were 
included in our review (comprised of 15 independent studies [61,62,67,68]). The most common reasons 
for exclusion were studies reporting non-psychosocial predictors only, ineligible patient populations, 
and those only reporting prevalence of non-adherence (see Appendix II for full reasons for exclusion 
list).  
3.2 Study characteristics 
3.2.1 Design 
Table 1 provides a descriptive summary of the studies included in this review. Over half of the included 
studies were conducted in the USA [58,61,62,67-70,72,74] and the majority of studies adopted a 
prospective cohort design [58,60-69,71,73] with follow up ranging from 3 to 24 months. 
The total sample size for all included studies was 7401 (median = 208; range = 73 – 2118). Mean age of 
all participants was 61.8 years (n = 16; SD = 4.54; range = 53 – 75), 67.2% were male (n = 16; SD = 10.55; 
range = 47.7 – 84) and 85.1% were white (n = 10; SD = 7.86; range = 66 – 96). 
3.2.2 Outcomes 
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Different methods were used to measure medication adherence. Eight studies [59,61,66,69,70,72-74] 
used validated self-report questionnaires such as the Morisky Medication Adherence Scale (MMAS, 4-
items). Six studies [58,60,63-65,71] used non-validated self-report methods such as telephone 
interviews and three studies [62,67,68] used a Medication Event Monitoring System (MEMS) with cut-
offs of either 75% [67,68] or 80% [62]. 
Adherence to aspirin alone was the most frequently measured drug [62,67,68,70,71] while four studies 
[59,60,69,72] measured use of aspirin, β-blockers, lipid-lowering agents, and ACE inhibitors/ARBs. Six 
studies did not specify the type of cardiac medication in which adherence was being measured [61,64-
66,73,74]. Rates of non-adherence based on medication class can be seen in Table 2.  
3.2.3 Quality assessment 
Based on QUIPS tool criteria [55], all included studies were rated as ‘good’ [60-62,64-69,72-74] or ‘fair’ 
[58,59,63,70,71] quality. Methodological issues among ‘fair’ rated studies included not reporting 
baseline comparisons between responders and non-responders [58,59,70,71] and inadequate reporting 
of all predictor variables/covariates [58,59] (see Appendix III for full quality assessment screening). 
3.3 Psychosocial predictors of medication adherence 
Table 3 provides an overview of psychosocial predictors and their relationship with medication non-
adherence.  
3.3.1 Mood-related factors 
Depression 
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Eight of ten studies found depression to be associated with non-adherence [58-62,67-69]. Six of the 
eight were rated as ‘good’ quality [60-62,67-69] and seven were prospective cohort studies [58,60-
62,67-69]. 
Three prospective studies [62,67,68] found depression predicted aspirin non-adherence while another 
study [58] found an associated between depression and non-adherence to ACE inhibitors/ARBs and 
lipid-lowering agents. Four studies [59-61,69] that found an effect did not specify cardiac drug class. 
Two studies using the same patient sample compared patients post-ACS based on the course [67] and 
severity [68] of depression. Patients with persistent depression (baseline and 3 months follow up) were 
more likely to be non-adherent to MEMS-measured aspirin compared to patients with remittent 
depression or those without depression [67]. Additionally, patients with severe depression were over 
three times more likely to be non-adherent to aspirin post ACS compared to those without depression 
[68]. One study [60] found depression predicted non-adherence but only in patients younger than 65 
years. 
Two studies found no relationship between depression and medication adherence [63,71]. One study 
[63] found depression did not significantly predict non-adherence to aspirin, antihypertensives, and 
lipid-lowering agents. Another small study [71] also found no effect between depression and medication 
non-adherence. Depression was also found not to be associated with non-adherence to β-blockers in 
one study, but did predict non-adherence to other cardiac medicines [58]. 
Type D personality 
Type D is considered the ‘distressed’ personality type and is comprised of two domains, negative 
affectivity and social inhibition.  Two studies [66,73] that investigated Type D as a predictor of 
medication non-adherence found patients classified as having Type D personality were more likely to be 
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non-adherent at 3 months [73] and 6 months [66] following ACS. When assessed categorically, only 
negative affectivity predicted non-adherence in both studies. Self-efficacy was found to partially 
mediate the relationship between negative affectivity and medication non-adherence in one study [66]. 
3.3.2 Cognitive-related factors 
Treatment beliefs 
Three studies found evidence that treatment beliefs predicted medication non-adherence [58,70,72], 
however, there was inconsistency in the findings. Using the Beliefs about Medicines Questionnaire 
(BMQ), a prospective study found beliefs about drug necessity (Specific-Necessity) and also concerns 
about taking medication (Specific-Concern) predicted non-adherence to β-blockers, ACE inhibitors/ARBs, 
and lipid-lowering agents [58]. A cross-sectional study [72] found that lower scores on the Specific-
Necessity subscale of the BMQ predicted lower self-reported adherence following ACS. Conversely, a 
cross-sectional study of ‘fair’ quality [70] found only the Specific-Concern subscale predicted non-
adherence to aspirin after ACS. 
3.3.3 Social contextual factors 
Few studies have measured the effect of social support in predicting medication adherence following 
ACS. One prospective study [64] measured practical and emotional support in patients following ACS. 
Patients with lower practical support were more likely to be non-adherent to medication 12 months on, 
however, there was no such effect for emotional support. Additionally, one cross-sectional study [59] 
found that lower levels of social support predicted medication non-adherence after controlling for 
sociodemographic and clinical factors. 
One prospective study measured social network size, here considered a proxy measure of social support 
[65], but found no effect on medication non-adherence 12 months after ACS. This study did, however, 
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find that self-reported partner stress (patients rated this based on preceding 6 months prior to ACS 
onset) was associated with poor medication adherence. 
There were other psychosocial factors that were only investigated in singular studies. One study [62] 
measured cognitive (dysfunctional attitudes), behavioural (engaging in pleasant events), and 
psychosocial (role transitions, interpersonal conflict) vulnerabilities to determine their association with 
depression and medication non-adherence. Role transitions and interpersonal conflict were found to 
independently predict MEMS-measured aspirin non-adherence 3 months after ACS. One cross-sectional 
study found that life chaos – having a chaotic lifestyle and environment – was associated with self-
reported non-adherence in patients with a history of AMI [74]. Another study [71] found that patients 
exhibiting symptoms for post-traumatic stress disorder (PTSD) were more likely to be non-adherent to 
aspirin following ACS. 
3.4 Meta-analysis 
Depression was the only psychosocial predictor identified with sufficient data for a meta-analysis. Figure 
2 shows the pooled effect sizes (n = 5058; median = 492) for depression as a significant predictor of non-
adherence (k = 7, [58-61,63,68,69]), OR = 2.00, 95% CI 1.57-3.33, p = .015. Three studies were excluded 
from this analysis based on unsuitable data [71] or not having an independent study sample [62,67]. An 
I2 statistic of 61.9% suggests moderate to substantial statistical heterogeneity between studies. 
Publication bias was determined using a funnel plot (see Appendix IV). Additionally, Egger's test for 
small study effects indicated no significant bias (p = .176) though power was an issue with only seven 
studies and there was some indication of missing small studies with negative results. A sensitivity 
analysis using the trim and fill method [91] generated a pooled random effects estimate of OR = 1.90 
(95% CI 1.53-2.37), which suggested the pooled effect size is likely to be robust to potential publication 
bias. 
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Figure 3 shows the pooled effect sizes for depression stratified by medication classification. When 
medication class was not specified (n = 3232; median = 480.5) depression was significantly associated 
with non-adherence (k = 4 [59-61,69]), OR = 2.05, 95% CI 1.39-3.03, p = .003. There were no other 
effects found between depression and non-adherence to specific cardiac medications (ACE 
inhibitors/ARBs, lipid-lowering agents, β-blockers, aspirin or antihypertensives). 
4. Discussion 
To our knowledge, this is the first study to review and meta-analyse the evidence regarding psychosocial 
determinants of medication non-adherence following ACS. Our study included 17 studies that assessed a 
range of psychosocial factors relating to patients’ mood, cognition and social context.  
Depression was the most commonly studied psychosocial factor and was found to predict adherence in 
the majority of studies (eight of ten studies; [58-62,67-69]. Our analysis revealed that patients exhibiting 
depressive symptoms following ACS were twice as likely to be non-adherent compared to non-
depressed. When the class of medication was not specified (i.e., any cardiac medication), depression 
was associated with a 2.05 increased risk of non-adherence. There was no such association found 
between depression and other specific cardiac medications, however, this is likely to have been affected 
by the small number of studies testing these relationships. Our findings are congruous with previous 
studies that have found strong associations between depression and medication non-adherence in 
patients with CAD [32,34,37].  
We found patients classified as having Type D or ‘distressed’ personality type were more likely to be 
non-adherent to medication following ACS. Individuals with Type D personality have a propensity for 
negative affectivity (i.e., worry and stress) and social inhibition (i.e., anxiety and apprehension) [92]. Our 
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review found evidence that when measured categorically, negative affectivity predicted adherence 
while social inhibition did not. 
In addition to mood-related factors, this review also provided some evidence that cognitive factors such 
as treatment beliefs based on the Necessity-Concerns Framework (NCF) were associated with 
medication non-adherence [26]. Stronger beliefs about needing medicines (necessity beliefs) coupled 
with a lack of concern about medicines potentially causing harm (concern beliefs) predicted better 
adherence, however, there was insufficient data available to conduct a meta-analysis of the three 
studies included. These finding support previous studies that have used the NCF to predict medication 
adherence in other cardiac conditions including CHD [27], heart failure [28], and hypertension [29]. 
There was some evidence that the social context or situation of patients affects medication-taking 
behaviour. Findings from single studies revealed that increased partner stress, interpersonal conflict, 
number of role transitions, and perceived life chaos are all factors associated with medication non-
adherence. In addition, lower perceived social support and, in particular, practical support was also 
found to predict medication adherence. While this evidence is compelling, there are not enough studies 
investigating the role of such social contextual factors to draw firm conclusions. 
We believe that this review is the first to specifically identify psychosocial factors related to post-ACS 
medication use. A recent review by Chen et al. (2015) [22] did investigate predictors of medication 
adherence post-ACS, however, it focused on sociodemographic and clinical factors rather than 
psychosocial correlates. There was little overlap between the two reviews in terms of eligible studies 
with just two included in both reviews [58,68]. 
The link between depression and cardiac disease has long been established and the mechanisms behind 
this relationship widely discussed [40]. It has been posited that negative health behaviours may mediate 
the relationship between depression and risk of acute cardiac episodes [31]. The recent Coronary 
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Psychosocial Evaluation Studies (COPES) trial investigated the effect of an enhanced depression 
intervention to improve adherence to secondary prevention behaviours following ACS [93]. Findings 
from the COPES trial highlight the need for future work to focus on identifying specific adherence 
intervention strategies that can be implemented alongside treatment for depression. 
Negative beliefs about treatment or about illness more generally may act as a barrier to adherence. 
Challenging treatment beliefs and illness perceptions may be a useful strategy to improve rates of 
adherence, however, the effectiveness of interventions have been mixed [94]. Petrie et al. [95] 
developed an intervention to change how patients perceived their illness following MI. Patients 
receiving the intervention were less likely to believe their illness was permanent and felt more in control 
of their recovery. They also reported fewer angina symptoms and returned to work quicker than those 
in the control group. In a similar study, Broadbent et al. [96] found their intervention improved patients’ 
understanding of their condition and altered beliefs about illness causation. The intervention group 
again returned to work quicker than controls. Further work should focus on developing novel behaviour 
change techniques focused on the cognitive processes involved in making treatment decisions and 
following treatment advice.  
This review found some evidence that social support was associated with medication adherence, 
specifically practical support. DiMatteo [41] investigated the association between social support and 
treatment adherence across diseases and conditions.  Findings from 29 studies revealed that practical 
support was strongly correlated with treatment adherence and that the risk of non-adherence was 
almost double among patients lacking practical support. Promoting existing contacts such as friends and 
family to support patients with the practical aspects of drug purchasing and administration has been 
suggested as an effective strategy to improve adherence [42].  
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Previous evidence has shown that treatment non-adherence is a significant barrier to recovery after an 
ACS event. Poor clinical responses to treatment can be easily interpreted as an issue with the therapy 
rather than attributed to a problem with adherence [97]. This may lead to needless dose increases, 
unnecessary augmentation of therapy with additional medications, or loss of clinical benefit due to 
discontinuation of the medicine for perceived lack of effect. Further, this can affect clinical outcomes 
such as increasing the risk of adverse events. Identifying factors associated with medication non-
adherence is important in order to highlight patients at risk and to offer additional support for those 
experiencing difficulties with their medications. 
4.1 Clinical implications 
Adherence is a complex health behaviour that is unsurprisingly associated with a range of psychosocial 
factors. Routinely screening for psychosocial factors such as depression, treatment beliefs, and levels of 
social support after an ACS event may be an effective approach to identify individuals at risk of 
adherence problems. The BDI and PHQ are self-report measures that are both well-validated and easy to 
administer in an acute setting and may be a suitable option for clinicians to use routinely to screen for 
depression in patients with ACS [98]. 
In addition, the BMQ has shown good reliability in measuring patients’ beliefs about drug necessity and 
concern in cardiac populations [27-29] and could be utilised in clinical settings to recognise maladaptive 
beliefs around medication use. One strategy could be to administer the BMQ prior to hospital discharge 
to identify patients’ attitudes towards medications. This information could then be discussed during a 
subsequent follow up appointment with their primary care provider. A strategy such as this would 
provide an opportunity for an open discussion between patient and care provider where any negative 
beliefs or misconceptions about medicines could be identified and treated accordingly. 
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The findings from this review highlight the importance of psychosocial factors in terms of medication 
use, however, there may be wider influences on recovery following ACS. There is evidence that 
psychosocial factors such as illness perceptions [99-101] and depression [102-104] predict other 
behavioural components of a cardiac treatment regimen such as smoking cessation and exercise 
training/rehabilitation. Thus, addressing psychosocial factors could potentially have an even larger role 
in improving medical outcome in cardiac patients. 
There are a variety of methods to measure medicine adherence including self-report questionnaires, pill 
counts, frequency of dispensing, timing of prescription refills, electronic monitors and biochemical 
indicators. There are pros and cons to each method of measurement [105]. For example, self-report 
questionnaires are cheap and easy to administer in most clinical settings, however, may underestimate 
non-adherence because of patients’ desire to be perceived as compliant (social desirability bias). 
Electronic monitors provide real-time information about when a patient accesses their pill container, 
however, there is no guarantee that the medicine is taken after the container is accessed. Finding the 
most appropriate method to measure adherence is a contentious issue and despite a range of different 
methods available, there is currently no ‘gold standard’ to measure adherence that is equally accurate, 
sensitive, and practical to use [3]. This presents a challenge for those working in adherence research and 
highlights the need for further work to be done in developing appropriate tools for measurement [106]. 
4.2 Limitations 
- The decision to search only for articles in English was based on convenience. As a result, 
potentially relevant non-English articles would have been missed. In addition, we only searched 
for articles published between 2000 and 2014 meaning that pre-2000 publications were 
overlooked. This decision was based on the publication date of the CURE trail which advocated 
the use of DAPT to treat ACS [47]. We expected to find some studies that had investigated the 
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role of psychosocial factors in determining DAPT adherence, however, our search strategy found 
none.  
- Only the lead researcher (JC) manually screened all articles, thus limiting the validity of the 
search process. Co-authors (VA and JW) were only partially involved in full-text screening using 
the inclusion criteria. Ideally, multiple members of the research team should screen all articles 
identified in the search process.  
- When undertaking a systematic review, there is always a risk of publication bias where negative 
studies of predictors not being associated with non-adherence might be less likely to get 
published. We tried to ameliorate this issue by undertaking a grey literature search of 
unpublished work. None of the included studies were identified using this search strategy. 
- A number of the studies did not use validated measures of medication adherence which limits 
the strength of their findings. We decided not to exclude studies based on the method used to 
measure adherence as this would have significantly reduced the number of included articles. 
This particular point is indicative of a wider issue around measuring medication adherence. 
4.3 Conclusions 
This review and meta-analysis found evidence that psychosocial factors are associated with medication 
adherence following ACS. Firstly, we found that depression was a significant risk factor for non-
adherence and along with individuals classified as having a Type D personality could be routinely 
screened for during hospitalisation. Secondly, there was some evidence that cognitive-related factors 
such as treatment beliefs also predicted medication adherence. Emphasising the necessity of medicines 
in improving health and addressing concerns about medicines may be a useful strategy to improve 
adherence. Finally, offering better support for patients and placing a greater emphasis on understanding 
their social situation may also provide an avenue for treatment for patients with ACS. Based on the 
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findings of this review, we suggest that psychosocial factors are important in determining adherence 
and future work should focus on how to target these types of patient-related factors to improve health 
outcomes following ACS. 
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Author Year Country 
Study 
design 
Setting 
Follow 
up 
(months) 
Sample 
Sample 
size 
Sample demographics 
Allen La Pointe 
et al. [58] 
2011 USA PC 
Inpatients, 
41 hospitals 
3 ACS 973 
β-blocker cohort: Mean age = 59; Male = 
70%; White = 81% 
        
ACEi/ARBs cohort: Mean age = 59; Male = 
70%; White = 79% 
                
LL therapy cohort: Mean age = 58; Male = 
69%; White = 82% 
Castellano et 
al. [59] 
2014 Various CS 
Outpatients, 
64 clinics 
N/A AMI 2118 Mean age = 64 
                Male = 64% 
Jin et al. [60] 2014 China PC 
Inpatients, 1 
hospital 
24 ACS 469 Mean age = 62 
                Male = 70% 
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Kronish et al. 
[61] 
2006 USA PC 
Inpatients, 3 
hospitals  
3 ACS 492 Mean age = 61 
                Male = 59% 
Kronish et al. 
[62] 
2014 USA PC 
Inpatients, 3 
hospitals  
3 ACS 169 Mean age = 59 
        
Male = 56% 
        
White = 86% 
                  
McGee et al. 
[63] 
2006 Ireland PC 
Inpatients, 
39 hospitals  
12 ACS 681 Mean age = 63 
        
Male = 76% 
                White = 87% 
Molloy et al. 
[64] 
2008 England PC 
Inpatients, 4 
hospitals 
12 ACS 262 Mean age = 61 
                Male = 77% 
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Molloy et al. 
[65] 
2008 England PC 
Inpatients, 4 
hospitals 
12 ACS 193 Mean age = 61 
        
Male = 77% 
                White = 86% 
Molloy et al. 
[66] 
2012 England PC 
Inpatients, 1 
hospital 
6 ACS 165 Mean age = 62 
        
Male = 84% 
        
White = 86% 
                  
Rieckmann et 
al. [67] 
2006 USA PC 
Inpatients, 2 
hospitals 
3 ACS 165 Mean age = 59 
        
Male = 48% 
                White = 87% 
Rieckmann et 
al. [68] 
2006 USA PC 
Inpatients, 2 
hospitals 
3 ACS 172 Mean age = 59 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
39 
 
        
Male = 55% 
                White = 87% 
Romanelli et 
al. [69] 
2011 USA PC 
Inpatients, 1 
hospital 
4 AMI 153 Mean age: 75 
        
Male = 56% 
                White = 92% 
Schulman-
Marcus et al. 
[70] 
2013 USA CS - N/A ACS 510 - 
Shemesh et al. 
[71] 
2004 Isreal PC 
Outpatients, 
1 clinic 
12 MI 73 Mean age = 53 
        
Male = 80% 
                  
Sud et al. [72] 2005 USA CS 
Outpatients, 
1 hospital 
N/A ACS 208 Mean age = 65 
        
Male = 61% 
                White = 96% 
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Williams et al. 
[73] 
2011 Scotland PC 
Inpatients, 1 
hospital 
3 MI 192 Mean age = 66 
                Male = 72% 
Zullig et al. 
[74] 
2013 USA CS 
Outpatients, 
1 hospital 
N/A MI 406 Mean age = 61 
        
Male = 72% 
                White = 66% 
 
 
Author 
Psychosocial predictors 
Psychosocial 
predictor measures 
Outcome Outcome measure Outcome drug(s) 
Quality 
score 
Allen La 
Pointe et 
al. [58] 
Treatment beliefs BMQ-Specific 
Self-reported 
adherence 
Telephone 
interview (1 item) 
β-blocker Fair 
 
Depression -   ACEi/ARBs  
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        LL therapy   
Castellano 
et al. [59] 
Depression PHQ-9 
Self-reported 
adherence 
MMAS-4 
Does not break down 
by drug type (in 
analysis) 
Fair 
  
Social support -         
Jin et al. 
[60] 
Depression PHQ-9 
Self-reported 
adherence 
Telephone 
interview (1-2 
items) 
Does not break down 
by drug type (in 
analysis) 
Good 
  
            
Kronish et 
al. [61] 
Depression BDI 
Self-reported 
adherence 
MMAS-4 
Does not break down 
by drug type 
Good 
           
Kronish et 
al. [62] 
Depression BDI 
Indirect 
measure of 
adherence 
MEMS (80% 
cutoff) 
Aspirin Good 
 
Cognitive vulnerability DAS-24     
 
Behavioural vulnerability PES-E     
  
Psychosocial vulnerability 
Interpersonal 
conflict = IPARS & 
Role transitions = 
        
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
42 
 
DAS 
McGee et 
al. [63] 
Depression HADS-D/BDI-FS 
Self-reported 
adherence 
Non-validated 
questionnaire 
Aspirin Fair 
 
    Antihypertensives  
  
        LL therapy   
Molloy et 
al. [64] 
Social support 
Interview, measure 
devised by Berkman 
et al. (1992) 
Self-reported 
adherence 
Telephone 
interview (3 items) 
Does not break down 
by drug type 
Good 
  
Depression BDI         
Molloy et 
al. [65] 
Social network size 
Questionnaire 
devised by Cohen et 
al. (1997) (12 items) 
Self-reported 
adherence 
Telephone 
interview (3 items) 
Does not break down 
by drug type 
Good 
 
Partner stress 
Clinical interview (1 
item) 
    
 
DS-16 (negative 
affectivity 
subscale) 
        
Molloy et 
al. [66] 
Type D personality DS-14 
Self-reported 
adherence 
MARS 
Does not break down 
by drug type 
Good 
 
Self-efficacy Measure devised by 
Rohrbaugh et al. 
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(2004) (10 items) 
 
Depression BDI     
  
Social support 
Measure devised by 
Berkman et al. 
(2003) (7 items) 
        
Rieckmann 
et al. [67] 
Depression BDI 
Indirect 
measure of 
adherence 
MEMS (75% 
cutoff) 
Aspirin Good 
 
      
  
            
Rieckmann 
et al. [68] 
Depression BDI 
Indirect 
measure of 
adherence 
MEMS (75% 
cutoff) 
Aspirin Good 
 
      
  
           
Romanelli 
et al. [69] 
Depression BDI 
Self-reported 
adherence 
MOSSAS 
Does not break down 
by drug type (in 
analysis) 
Fair 
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Schulman-
Marcus et 
al. [70] 
Treatment beliefs BMQ-Specific 
Self-reported 
adherence 
MMAS Aspirin Fair 
Shemesh 
et al. [71] 
PTSD symptoms IES 
Self-reported 
adherence 
Interview & 
biomarker test 
(thromboxane) 
Aspirin Fair 
 
Depression 
SCL-90-R 
(depression 
subscale) 
    
  
Global distress 
SCL-90-R (global 
distress subscale) 
        
Sud et al. 
[72] 
Treatment beliefs BMQ 
Self-reported 
adherence 
MMAS-4 
Does not break down 
by drug type (in 
analysis) 
Good 
 
      
  
            
Williams 
et al. [73] 
Type D personality DS-14 
Self-reported 
adherence 
MARS 
Does not break down 
by drug type 
Good 
  
            
Zullig et al. 
[74] 
Life chaos 
Adaptation of 
CHAOS (6 items) 
Self-reported 
adherence 
MMAS-4 
Does not break down 
by drug type 
Good 
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Notes. 
- = Not reported 
N/A = Not applicable 
 
Definitions. 
PC = Prospective cohort 
CS = Cross-sectional 
ACS = Acute coronary syndrome 
AMI = Acute myocardial infarction 
MI = Myocardial infarction 
ACEi = Angiotensin converting enzyme inhibitor 
ARBs = Angiotensin II receptor blockers 
LL therapy = Lipid-lowering therapy 
BMQ = Beliefs about Medicines Questionnaire [26] 
PHQ-9 = The Patient Health Questionnaire [75] 
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BDI = Beck Depression Inventory [76] 
DAS-24 = Dysfunctional Attitudes Scale [77] 
PES-E = Pleasant Events Schedule for the Elderly [78] 
IPARS = Interpersonal Problem Area Rating Scale [79] 
DAS = Dyadic Adjustment Scale [80]  
HADS-D = Hospital Anxiety and Depression Scale (depression subscale) [81] 
BDI-FS = Beck Depression Inventory-Fast Scale [82] 
DS-16 = The Type D Scale-16 [83] 
IES = Impact of Event Scale [84] 
SCL-90-R = Symptom Checklist-90-Revised [85] 
DS-14 = The Type D Scale-14 [86] 
CHAOS = Confusion, Hubbub, and Order Scale [87] 
MMAS-4 = Morisky Medication Adherence Scale-4 [88] 
MEMS = Medication Event Monitoring System 
MARS = Medication Adherence Report Scale [89] 
MOSSAS = Medical Outcomes Study Specific Adherence Scale [90] 
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Table 1. Data extraction table for the included studies 
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  Drug classes 
Follow up Aspirin Studies β-blocker Studies ACEi/ARBs Studies LL therapy Studies 
Class not 
specified Studies 
3 months 37%† - 42%* [68,67] 23% [58, 62] 26% [58] 23% [58] 30%* [61] 
12 months 13% - 16% [63,71] - 
 
- 
 
16% [63] 44% - 50% [65,64] 
24 months 68% [60] 71% [60] 67% [60] 75% [60] - 
 Cross-sectional 13% [72] 20% [72] 44% [72] 24% [72] 43% - 55% [74,72,59] 
           Notes. 
          Studies where rates of medication non-adherence not reported [66,69,70,73] 
     
           † = Non-adherence rates for moderate/severe depression subgroup 
      * = Non-adherence rates for persistently depressed subgroup 
      
           Table 2. Rates of cardiac medication non-adherence according to drug class and follow up 
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Predictive factors Author Year 
Quality 
score 
Study 
design 
Main analysis Covariates included Effect 
Mood-related factors 
       
    Depression (n = 10) 
       
        Significant effect 
Allen La 
Pointe et al. 
[58] 
2011 Fair PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours, 
BMQ scores 
ACEi/ARBs: OR = 1.33; 95% CI 1.01-
1,76; p < .05 
 
            
LL therapy: OR = 1.74; 95% CI 1.36-
2.23; p < .05 
 
Castellano 
et al. [59] 
2014 Fair CS 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours 
OR = 1.07; 95% CI 1.04-1.09; p < 
.001 
 
Jin et al. 
[60] 
2014 Good PC 
Multivariate 
logistic 
regression 
SocDem, 
comorbidity score 
OR = 2.62; 95% CI 2.03-3.38; p < 
.001 
 
Kronish et 
al. [61] 
2006 Good PC 
Multivariate 
logistic 
regression 
SocDem, 
comorbidity score 
OR = 2.00; 95% CI 1.05-3.70, p < .05 
 
Kronish et 
al. [62] 
2014 Good PC 
Multivariate 
linear regression 
SocDem, 
comorbidity score, 
depression 
vulnerabilities 
Aspirin: beta = 0.42; p = .04 
 
Rieckmann 
et al. [67] 
2006 Good PC χ² analysis N/A Aspirin: χ² = 11.5; p = .01 
 
Rieckmann 
et al. [68] 
2006 Good PC 
Multivariate 
logistic 
regression 
SocDem, 
comorbidity score 
Aspirin: OR = 3.7; 95% CI 1.3-10.6; p 
< .05 
 
Romanelli et 
al. [69] 
2011 Good PC ANOVA N/A F = 4.80; p = .03 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
50 
 
        Non-significant effect 
McGee et 
al. [63] 
2006 Fair PC 
Logistic 
regression 
Unadjusted 
Aspirin: OR = 2.0; 95% CI 0.8-3.3; p 
= .11 
       
Antihypertensives: OR = 1.1; 95% CI 
0.6-2.0; p = .73 
 
            
LL therapy: OR = 1.7; 95% CI 0.8-
3.3; p = .16 
 
Shemesh et 
al. [71] 
2004 Fair PC 
Mean difference 
in depression 
scores 
N/A 
Aspirin: M: 22.6 ± SD: 11.8 vs. M: 
22.9 ± SD: 11.8; p = .93 
 
Allen La 
Pointe et al. 
[58] 
2011 Fair PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours, 
BMQ scores 
β-blocker: OR = 1.28; 95% CI 0.95-
1.73; p > .05 
    Type D personality (n = 2) 
       
        Significant effect 
Molloy et al. 
[66] 
2012 Good PC 
Multivariate 
linear regression 
Baseline adherence 
scores 
beta = 0.73; p < .01 
  
Williams et 
al. [73] 
2011 Good PC 
Multivariate 
linear regression 
SocDem, clinical beta = 0.48; p < .01 
Cognitive-related factors 
       
    Necessity beliefs (BMQ; n = 3) 
       
        Significant effect 
Allen La 
Pointe et al. 
[58] 
2011 Fair PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours, 
depression 
β-blocker: OR = 0.94; 95% CI 0.90-
0.98; p < .05 
       
ACEi/ARBs: OR = 0.93; 95% CI 0.88-
0.98; p < .05 
 
            
LL therapy: OR = 0.95; 95% CI 0.91-
0.99; p < .05 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
51 
 
 
Sud et al. 
[72] 
2005 Good CS 
Multivariate 
linear regression 
SocDem, 
comorbidity score 
beta = -0.262; p = .001 
        Non-significant effect 
Schulman-
Marcus et 
al. [70] 
2013 Fair CS 
Multivariate 
logistic 
regression 
SocDem 
Aspirin: statistics not reported, only 
that it was non-significant 
    Concern beliefs (BMQ; n = 3) 
       
        Significant effect 
Allen La 
Pointe et al. 
[58] 
2011 Fair PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours, 
depression 
β-blocker: OR = 1.10; 95% CI 1.05-
1.16; p < .05 
       
ACEi/ARBs: OR = 1.06; 95% CI 1.01-
1.11; p < .05 
 
            
LL therapy: OR = 1.09; 95% CI 1.04-
1.14; p < .05 
 
Schulman-
Marcus et 
al. [70] 
2013 Fair CS 
Multivariate 
logistic 
regression 
SocDem 
Aspirin: OR = 1.42; 95% CI 1.13-
1.79; p < .05 
        Non-significant effect 
Sud et al. 
[72] 
2005 Good CS 
Multivariate 
linear regression 
SocDem, 
comorbidity score 
beta = 0.033; p = .70 
Social contextual factors 
       
    Social support (n = 3) 
       
        Significant effect 
Castellano 
et al. [59] 
2014 Fair CS 
Multivariate 
logistic 
regression 
SocDem, clinical, 
health behaviours 
OR = 0.94; 95% CI 0.92-0.96; p < 
.001 
 
Molloy et al. 
[64] 
2008 Good PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
depression 
OR = 0.47; 95% CI 0.23-0.94; p = .03 
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        Non-significant effect 
Molloy et al. 
[65] 
2008 Good PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
negative affectivity, 
relationship stress 
OR = 0.72; 95% CI 0.31-1.67; p = .44 
    Relationship stress (n = 1) 
       
        Significant effect 
Molloy et al. 
[65] 
2008 Good PC 
Multivariate 
logistic 
regression 
SocDem, clinical, 
negative affectivity, 
social network size 
OR = 2.92; 95% CI 1.21-7.08, p = .02 
    Role transitions (n = 1) 
       
        Significant effect 
Kronish et 
al. [62] 
2014 Good PC 
Multivariate 
linear regression 
SocDem, 
comorbidity score, 
depression 
Aspirin: beta = 3.32; p = .02 
    Interpersonal conflict (n = 1) 
       
        Significant effect 
Kronish et 
al. [62] 
2014 Good PC 
Multivariate 
linear regression 
SocDem, 
comorbidity score, 
depression 
Aspirin: beta = 3.78; p = .03 
    Life chaos (n = 1) 
       
        Significant effect 
Zullig et al. 
[74] 
2013 Good CS 
Multivariate 
logistic 
regression 
SocDem, health 
literacy scores 
OR = 1.07; 95% CI 1.02-1.12; p < .05 
    PTSD (n = 1) 
       
        Significant effect 
Shemesh et 
al. [71] 
2004 Fair PC 
Mean difference 
in depression 
scores 
N/A 
Aspirin: p = .008 (M & SD not 
reported) 
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Notes. 
Did not breakdown by drug type in analysis unless otherwise stated. 
 Definitions. 
ACEi = Angiotensin converting enzyme inhibitor 
ARBs = Angiotensin II receptor blockers 
LL therapy = Lipid-lowering therapy 
PC = Prospective cohort 
CS = Cross-sectional 
BMQ = Beliefs about Medicines Questionnaire [26] 
SocDem = Sociodemographic factors 
PTSD = Post-traumatic stress disorder 
OR = Odds ratios 
CI = Confidence intervals 
M = Mean 
SD = Standard deviation 
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Table 3. Analyses and effects found between psychosocial predictors and medication non-adherence 
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Figure 1. PRISMA flow diagram showing the study selection process 
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Figure 2. Forrest plot showing pooled effect sizes for selected studies that measured depression as a 
predictor of medication adherence 
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Figure 3. Forrest plot showing pooled effect sizes for studies that measured depression stratified by 
medication class 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
58 
 
Medline, EMBASE, PsycINFO, International Pharmaceutical Abstracts 
(treatment adherence or treatment nonadherence or treatment non-adherence or treatment non 
adherence or treatment compliance or treatment noncompliance or treatment non-compliance or 
treatment non compliance or treatment concordance or treatment discordance or treatment 
persistence or treatment nonpersistence or treatment non-persistence or treatment non persistence or 
treatment continuation or treatment discontinuation) OR (medic* adherence or medic* nonadherence 
or medic* non-adherence or medic* non adherence or medic* compliance or medic* noncompliance or 
medic* non-compliance or medic* non compliance or medic* concordance or medic* discordance or 
medic* persistence or medic* nonpersistence or medic* non-persistence or medic* non persistence or 
medic* continuation or medic* discontinuation) OR (drug* adherence or drug* nonadherence or drug* 
non-adherence or drug* non adherence or drug* compliance or drug* noncompliance or drug* non-
compliance or drug* non compliance or drug* concordance or drug* discordance or drug* persistence 
or drug* nonpersistence or drug* non-persistence or drug* non persistence or drug* continuation or 
drug* discontinuation) OR (pharmac* adherence or pharmac* nonadherence or pharmac* non-
adherence or pharmac* non adherence or pharmac* compliance or pharmac* noncompliance or 
pharmac* non-compliance or pharmac* non compliance or pharmac* concordance or pharmac* 
discordance or pharmac* persistence or pharmac* nonpersistence or pharmac* non-persistence or 
pharmac* non persistence or pharmac* continuation or pharmac* discontinuation) OR (regimen 
adherence or regimen nonadherence or regimen non-adherence or regimen non adherence or regimen 
compliance or regimen noncompliance or regimen non-compliance or regimen non compliance or 
regimen concordance or regimen discordance or regimen persistence or regimen nonpersistence or 
regimen non-persistence or regimen non persistence or regimen continuation or regimen 
discontinuation) 
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AND 
(("acute coronary syndrome" or "ACS" or "heart attack" or myocardial infarct* or "MI" or "acute 
myocardial infarction" or "AMI" or "STEMI" or "NSTEMI" or "coronary thrombosis" or "coronary 
occlusion" or "unstable angina" or "unstable angina pectoris") not (motivational interviewing or 
motivational-interviewing)) 
AND 
(antiplatelet or anti-platelet or dual antiplatelet therap* or dual-antiplatelet therap* or DAPT or DAT or 
aspirin or acetylsalicylic acid or ASA or clopidogrel or plavix or ticagrelor or brilinta or brilique or possia 
or prasugrel or ef?ient or thienopyridine or high dose statin or high-dose statin or high intensity statin or 
high-intensity statin or cardiac medic* or cardiac drug* or cardiac pharmaco* or heart medic* or heart 
drug*) 
Limits: English language, published between 2000-2014 
 
Cochrane Library 
(Title, Abstract, Keyword) - "adherence" or "non-adherence" or "nonadherence" or "non adherence" or 
"compliance" or "non-compliance" or "noncompliance" or "non compliance" or "concordance" or 
"discordance" or "persistence" or "non-persistence" or "nonpersistence" or "non persistence" or 
"continuation" or "discontinuation" 
AND 
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(Title, Abstract, Keyword) - "acute coronary syndrome" or "ACS" or "heart attack" or myocardial infarct* 
or "MI" or "acute myocardial infarction" or "AMI" or "STEMI" or "NSTEMI" or "coronary thrombosis" or 
"coronary occlusion" or "unstable angina" or "unstable angina pectoris" 
AND 
(Title, Abstract, Keyword) - "antiplatelet" or “anti-platelet” or "DAPT" or "DAT" or "aspirin" or "ASA" or 
“acetylsalicylic acid” or "clopidogrel" or "prasugrel" or "ticagrelor" or  "thienopyridine" or "statin" or 
“medicine” or “medication” or “drug” or “pharmacotherapy”) 
Limits: English language, published between 2000-2014 
 
Web of Science 
TS=("treatment adherence" or "treatment nonadherence" or "treatment non-adherence" or "treatment 
non adherence" or "treatment compliance" or "treatment noncompliance" or "treatment non-
compliance" or "treatment non compliance" or "treatment concordance" or "treatment discordance" or 
"treatment persistence" or "treatment nonpersistence" or "treatment non-persistence" or "treatment 
non persistence" or “treatment continuation" or “treatment discontinuation”) OR TS=(“medic* 
adherence" or "medic* nonadherence" or "medic* non-adherence" or "medic* non adherence" or 
"medic* compliance" or "medic* noncompliance" or "medic* non-compliance" or "medic* non 
compliance" or "medic* concordance" or "medic* discordance" or "medic* persistence" or "medic* 
nonpersistence" or "medic* non-persistence" or "medic* non persistence" or “medic* continuation" or 
“medic* discontinuation”) OR TS=("drug* adherence" or "drug* nonadherence" or "drug* non-
adherence" or "drug* non adherence" or "drug* compliance" or "drug* noncompliance" or "drug* non-
compliance" or "drug* non compliance" or "drug* concordance" or "drug* discordance" or "drug* 
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persistence" or "drug* nonpersistence" or "drug* non-persistence" or "drug* non persistence" or 
“drug* continuation" or “drug* discontinuation”) OR TS=("pharmac* adherence" or "pharmac* 
nonadherence" or "pharmac* non-adherence" or "pharmac* non adherence" or "pharmac* 
compliance" or "pharmac* noncompliance" or "pharmac* non-compliance" or "pharmac* non 
compliance" or "pharmac* concordance" or "pharmac* discordance" or "pharmac* persistence" or 
"pharmac* nonpersistence" or "pharmac* non-persistence" or "pharmac* non persistence" or 
“pharmac* continuation" or “pharmac* discontinuation”) OR TS=("regimen adherence" or "regimen 
nonadherence" or "regimen non-adherence" or "regimen non adherence" or "regimen compliance" or 
"regimen noncompliance" or "regimen non-compliance" or "regimen non compliance" or "regimen 
concordance" or "regimen discordance" or "regimen persistence" or "regimen nonpersistence" or 
"regimen non-persistence" or "regimen non persistence" or “regimen continuation" or “regimen 
discontinuation”) 
AND 
TS=("acute coronary syndrome" or "ACS" or "heart attack" or myocardial infarct* or "MI" or "acute 
myocardial infarction" or "AMI" or "STEMI" or "NSTEMI" or "coronary thrombosis" or "coronary 
occlusion" or "unstable angina" or "unstable angina pectoris") NOT TS=("motivational interviewing" or 
"motivational-interviewing") 
AND 
TS=(antiplatelet or “anti-platelet” or dual antiplatelet therap* or dual-antiplatelet therap* or DAPT or 
DAT or aspirin or ASA or “acetylsalicylic acid” or clopidogrel or plavix or ticagrelor or brilinta or brilique 
or possia or prasugrel or ef?ient or  thienopyridine or “high dose statin” or “high-dose statin” or “high 
intensity statin” or “high-intensity statin” or cardiac medic* or cardiac drug* or cardiac pharmaco* or 
heart medic* or heart drug*) 
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Limits: English language, published between 2000-2014 
 
Applied Social Sciences Index and Abstracts (ASSIA) 
(ANYWHERE) - "adherence" or "non-adherence" or "nonadherence" or "non adherence" or 
"compliance" or "non-compliance" or "noncompliance" or "non compliance" or "concordance" or 
"discordance" or "persistence" or "non-persistence" or "nonpersistence" or "non persistence" or 
"continuation" or "discontinuation" 
AND 
(ANYWHERE) - "acute coronary syndrome" or "ACS" or "heart attack" or myocardial infarct* or "MI" or 
"acute myocardial infarction" or "AMI" or "STEMI" or "NSTEMI" or "coronary thrombosis" or "coronary 
occlusion" or "unstable angina" or "unstable angina pectoris" 
AND 
(ANYWHERE) - "antiplatelet" or “anti-platelet” or "DAPT" or "DAT" or "aspirin" or "ASA" or 
“acetylsalicylic acid” or "clopidogrel" or "prasugrel" or "ticagrelor" or "thienopyridine" or "statin" or 
“medicine” or “medication” or “drug” or “pharmacotherapy”) 
Limits: English language, published between 2000-2014 
 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
(TX "Medication Compliance") OR (MH "Patient Compliance") OR (MH "Guideline Adherence") OR 
(TX"adherence") OR (TX "discontinuation") OR (TX "compliance") 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
63 
 
AND 
(TX "Myocardial Infarction+") OR (TX "Acute Coronary Syndrome") OR (TX "Angina, Unstable") 
AND 
(TX "Statins+") OR (TX "Aspirin") OR (TX "Platelet Aggregation Inhibitors+") OR (TX "thienopyridine") OR 
(TX "clopidogrel") OR (TX "ticagrelor") OR (TX "prasugrel") OR (TX "dual antiplatelet therapy") OR (TX 
“cardiac medications”) 
Limits: English language, published between 2000-2014 
 
 
Open Grey 
(adheren* OR complian* OR persisten* OR discontinuati*) AND (medication* OR drug*) AND (cardi* OR 
coronary OR myocardial OR heart OR angina) lang:"en" 
Limits: English language, published between 2000-2014 
  
EthOS 
(acute coronary syndrome OR myocardial infarction) AND (adherence OR compliance OR persistence OR 
discontinuation) 
Limits: English language, published between 2000-2014 
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WorldCat – thesis & dissertations  
kw: adherence or kw: non-adherence or kw: nonadherence or kw: non w adherence or kw: compliance 
or kw: non-compliance or kw: noncompliance or kw: non w compliance or kw: concordance or kw: 
discordance or kw: persistence or kw: non-persistence or kw: nonpersistence or kw: non w persistence 
or kw: continuation or kw: discontinuation and yr: 2000 - 2014 and la= "eng" 
AND 
kw: acute w coronary w syndrome or kw: ACS or kw: heart w attack or (kw: myocardial and kw: infarct*) 
or kw: MI or kw: acute w myocardial w infarction or kw: AMI or kw: STEMI or kw: NSTEMI or kw: 
coronary w thrombosis or kw: coronary w occlusion or kw: unstable w angina or kw: unstable w angina 
w pectoris and yr: 2000 - 2014 and la= "eng" 
AND 
kw: antiplatelet or kw: anti-platelet or kw: DAPT or kw: DAT or kw: aspirin or kw: ASA or (kw: 
acetylsalicylic and kw: acid) or kw: clopidogrel or kw: prasugrel or kw: ticagrelor or kw: thienopyridine or 
kw: statin or kw. beta-blocker or kw. beta blocker or kw. angiotensin II receptor blocker or kw. ARB or 
kw. Angiotensin converting enzyme inhibitor or kw. Angiotensin-converting enzyme inhibitor or kw. ACE 
inhibitor or kw. ACEI and yr: 2000 - 2014 and la= "eng" 
Limits: English language, published between 2000-2014 
 
Appendix I: Full search strategy 
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Sourced during online database search     
Record Author Title Year Reason for exclusion 
1 Abraha, I. Statin compliance in the Umbrian population 2003 Non-ACS population 
2 Akincigil, A. Long-term adherence to evidence based secondary prevention 
therapies after acute myocardial infarction 
2008 Non-psychosocial 
factors only 
3 Akosah, K. O. Using a system wide care path to enhance compliance with 
guidelines for acute myocardial infarction 
2003 Adherence to 
guidelines 
4 Ali, R. C. Age and Persistent Use of Cardiovascular Medication After Acute 
Coronary Syndrome: Results from Medication Applied and 
Sustained Over Time 
2009 Non-psychosocial 
factors only 
5 Al-Khadra, S. Secondary prevention medication after myocardial infarction: 
Persistence in elderly people over the course of 1 year 
2014 Non-psychosocial 
factors only 
6 Allen Lapointe, N. M. Association between patient beliefs and medication adherence 
following hospitalization for acute coronary syndrome 
2011 Included 
7 Allonen, J. Mortality rate increases steeply with nonadherence to statin 
therapy in patients with acute coronary syndrome 
2012 Adherence as a 
predictor rather than 
outcome 
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8 Amador, P. C. Acute coronary syndromes in the elderly 2012 Non-psychosocial 
factors only 
9 Amar, J. Persistence of combination of evidence-based medical therapy in 
patients with acute coronary syndromes 
2008 Non-psychosocial 
factors only 
10 Amin, A. Improving the management of patients after myocardial infarction, 
from admission to discharge 
2006 Review 
11 Amin, A. P. Association of medical noncompliance and long-term adverse 
outcomes, after myocardial infarction in a minority and uninsured 
population 
2009 Prevalence only, not 
predictors 
12 Amin, A. P. The impact of medical non-compliance on long-term outcomes, 
following an acute coronary syndrome in a minority and uninsured 
population 
2009 Adherence as a 
predictor rather than 
outcome 
13 Amin, A. R. Long-term compliance with guideline-based medical therapies is 
the strongest predictor of event-free survival following acute 
coronary syndromes (ACS) and myocardial infarction (MI) 
2008 Adherence as a 
predictor rather than 
outcome 
14 Arif, H. Drug compliance after stroke and myocardial infarction: A 
comparative study 
2007 Non-psychosocial 
factors only 
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15 Armero, S. Rate of nuisance bleedings and impact on compliance to prasugrel 
in acute coronary syndromes 
2011 Prevalence only, not 
predictors 
16 Arnetz, J. E. Is patient involvement during hospitalization for acute myocardial 
infarction associated with post-discharge treatment outcome? An 
exploratory study 
2010 Non-psychosocial 
factors only 
17 Arnold, S. V. Physician adherence to the prescription of proven doses of 
secondary prevention medications after acute myocardial 
infarction. Insights from triumph and premier 
2012 Prescribing not 
adherence 
18 Austin, P. C. Comparing clinical and administrative data for profiling hospitals 
on post-discharge medication use by patients with acute 
myocardial infarction 
2008 Prescribing not 
adherence 
19 Austin, P. C. Factors associated with the use of evidence-based therapies after 
discharge among elderly patients with myocardial infarction 
2008 Prescribing not 
adherence 
20 Baber, U. Association of stent thrombosis and patterns of non-adherence to 
anti-platelet regimens in stented patients: Six month results of the 
paris registry 
2012 Adherence as a 
predictor rather than 
outcome 
21 Baglikov, A. Use of secondary prevention drug therapy in patients with acute 2013 Prescribing not 
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coronary syndrome after hospital discharge in Russian practice adherence 
22 Baglikov, A. Long-Term Compliance to Acetylsalicylic Acid in Patients after 
Acute Coronary Syndrome 
2012 Non-psychosocial 
factors only 
23 Bagnall, A. J. Optimal medical therapy for non-ST-segment-elevation acute 
coronary syndromes: exploring why physicians do not prescribe 
evidence-based treatment and why patients discontinue 
medications after discharge 
2010 Prevalence only, not 
predictors 
24 Ballesca, M. A. An electronic order set for acute myocardial infarction is associated 
with improved patient outcomes through better adherence to 
clinical practice guidelines 
2014 Adherence to 
guidelines 
25 Bally, K. Discontinuation of secondary prevention medication after 
myocardial infarction - the role of general practitioners and 
patients 
2013 Non-psychosocial 
factors only 
26 Batchelor, W. B. Racial differences in long-term outcomes after percutaneous 
coronary intervention with paclitaxel-eluting coronary stents 
2013 Non-ACS population 
27 Bauer, T. Guideline-recommended secondary prevention drug therapy after 
acute myocardial infarction: predictors and outcomes of 
2010 Prescribing not 
adherence 
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nonadherence 
28 Bauer, T. Guideline-recommended secondary prevention drug therapy after 
acute myocardial infarction: predictors and outcomes of 
nonadherence 
2010 Duplicate 
29 Bauleo, L. Evidence based drug therapy after acute myocardial infarction: 
Adherence and spatial differences in Rome and in the Lazio region 
2012 Non-psychosocial 
factors only 
30 Bertrand, M. E. Discontinuation of clopidogrel within the year following a non-ST-
segment elevation acute coronary syndrome has a deleterious 
effect: evidence from the CURE trial 
2007 Adherence as a 
predictor rather than 
outcome 
31 Berwanger, O. Effect of a multifaceted intervention on use of evidence-based 
therapies in patients with acute coronary syndromes in Brazil: the 
BRIDGE-ACS randomized trial 
2012 Non-psychosocial 
factors only 
32 Beyranvand, M. R. One-year outcome of patients with acute myocardial infarction 2007 Prevalence only, not 
predictors 
33 Bezin, J. Persistence to cardiovascular treatment in patients with acute 
coronary syndrome 
2013 Prevalence only, not 
predictors 
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34 Bezin, J. Use of the recommended drug combination for secondary 
prevention after a first occurrence of acute coronary syndrome in 
France 
2014 Prevalence only, not 
predictors 
35 Bi, Yufang Evidence-based medication use among Chinese patients with acute 
coronary syndromes at the time of hospital discharge and 1 year 
after hospitalization: Results from the Clinical Pathways for Acute 
Coronary Syndromes in China (CPACS) study 
2009 Non-psychosocial 
factors only 
36 Bird, G. C. Results of a survey assessing provider beliefs of adherence barriers 
to antiplatelet medications 
2011 Non-ACS population 
37 Blackburn, D. F. Adherence to statins, beta-blockers and angiotensin-converting 
enzyme inhibitors following a first cardiovascular event: A 
retrospective cohort study 
2005 Non-ACS population 
38 Boggon, R. Current prescribing of statins and persistence to statins following 
ACS in the UK: A MINAP/GPRD study 
2012 Prevalence only, not 
predictors 
39 Boggon, R. Clopidodgrel and statin prescribing patterns in acs patients - An 
observational study using linked secondary and primary care data 
in a UK population 2003-2009 
2011 Prescribing not 
adherence 
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40 Boggon, R. Clopidogrel discontinuation after acute coronary syndromes: 
Frequency, predictors and associations with death and myocardial 
infarction-a hospital registry-primary care linked cohort 
(MINAPGPRD) 
2011 Non-psychosocial 
factors only 
41 Boggon, R. Clopidogrel discontinuation after acute coronary syndromes: 
Frequency, predictors and associations with death and myocardial 
infarction-a hospital registry-primary care linked cohort 
(MINAPGPRD) 
2011 Duplicate 
42 Boggon, R. Clopidogrel discontinuation after acute coronary syndromes: 
Frequency, predictors and associations with death and myocardial 
infarction-a hospital registry-primary care linked cohort 
(MINAPGPRD) 
2011 Duplicate 
43 Böhm, M. Effects of nonpersistence with medication on outcomes in high-risk 
patients with cardiovascular disease 
2013 Non-ACS population 
44 Bonaca, M. P. Patterns of long-term thienopyridine therapy and outcomes in 
patients with acute coronary syndrome treated with coronary 
stenting: Observations from the timi-38 coronary stent registry 
2014 Non-psychosocial 
factors only 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
72 
 
45 Bourdes, V. Prediction of persistence of combined evidence-based 
cardiovascular medications in patients with acute coronary 
syndrome after hospital discharge using neural networks 
2011 Non-psychosocial 
factors only 
46 Boyden, T. F. Is cardiac rehabilitation associated with improved medication 
persistence following acute myocardial infarction? 
2011 Non-psychosocial 
factors only 
47 Bra, S. S. Long term adherence to dual antiplatelet therapy and late adverse 
cardiovascular events 
2008 Adherence as a 
predictor rather than 
outcome 
48 Bueno, H. One-year persistence and adherence rates to secondary 
prevention drugs prescribed in-hospital in patients with acute 
coronary syndromes. The ALASCA Study 
2010 Non-psychosocial 
factors only 
49 Butler, J. Adherence to therapy with beta blocking agents after acute MI 2003 Non-psychosocial 
factors only 
50 Butler, J. Outpatient adherence to beta-blocker therapy after acute 
myocardial infarction 
2002 Non-psychosocial 
factors only 
51 Cannon, C. P. Comparison of ticagrelor with clopidogrel in patients with a 
planned invasive strategy for acute coronary syndromes (PLATO): a 
2010 No measure of 
adherence 
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randomised double-blind study 
52 Carey, I. M. Statin use after first myocardial infarction in UK men and women 
from 1997 to 2006: Who started and who continued treatment? 
2012 Non-psychosocial 
factors only 
53 Cascini, S. Evidence based drug therapy and medium-long-term outcomes in 
very old patients after acute myocardial infarction 
2012 Adherence to 
guidelines 
54 Castellano, J. M. A Polypill Strategy to Improve Adherence: Results From the FOCUS 
Project 
2014 Included 
55 Chan, V. Pharmacotherapy after myocardial infarction: disease 
management versus usual care 
2008 Non-psychosocial 
factors only 
56 Chang, T. I. Kidney Function and Long-Term Medication Adherence after 
Myocardial Infarction in the Elderly 
2011 Prevalence only, not 
predictors 
57 Chapman, R. H. Association between adherence to calcium-channel blocker and 
statin medications and likelihood of cardiovascular events among 
US managed care enrollees 
2010 Non-ACS population 
58 Chiang, F. T. One-year outcome in patients with acute coronary syndromes: 
Taiwan ACS full spectrum registry 
2012 Adherence as a 
predictor rather than 
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outcome 
59 Chiang, F. T. Predictors of 1-year outcomes in the Taiwan Acute Coronary 
Syndrome Full Spectrum Registry 
2014 Prevalence only, not 
predictors 
60 Choudhry, N. K. Full coverage for preventive medications after myocardial 
infarction 
2011 Non-psychosocial 
factors only 
61 Choudhry, N. K. Rationale and design of the Post-MI FREEE trial: a randomized 
evaluation of first-dollar drug coverage for post-myocardial 
infarction secondary preventive therapies 
2008 Study design 
62 Choudhry, N. K. Untangling the relationship between medication adherence and 
post-myocardial infarction outcomes: Medication adherence and 
clinical outcomes 
2014 Prevalence only, not 
predictors 
63 Choudhry, N. K. Trends in adherence to secondary prevention medications in 
elderly post-myocardial infarction patients 
2008 Prevalence only, not 
predictors 
64 Chow, C. Use of secondary prevention medications in patients following 
admission with acute coronary syndrome in Australia-the 
concordance study 
2012 Prevalence only, not 
predictors 
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65 Chow, C. K. Association of diet, exercise, and smoking modification with risk of 
early cardiovascular events after acute coronary syndromes 
2010 Focus on lifestyle 
factors 
66 Ciniglio, C. Use of clopidogrel for acute coronary syndrome: Impact on clinical 
outcomes and costs in the United States 
2012 Adherence as a 
predictor rather than 
outcome 
67 Claessen, B. Stent thrombosis after primary pci for stemi in relation to non-
usage of dual antiplatelet therapy over time: Results of the 
horizons-ami trial 
2012 Adherence as a 
predictor rather than 
outcome 
68 Cole, J. A. Cardiovascular Medication Use Following Percutaneous Coronary 
Intervention: The Australian Experience 
2014 Non-ACS population 
69 Collet, J. P. Clinical outcomes according to permanent discontinuation of 
clopidogrel or placebo in the CHARISMA trial 
2009 No measure of 
adherence 
70 Corrao, G. Results of a retrospective database analysis of adherence to statin 
therapy and risk of nonfatal ischemic heart disease in daily clinical 
practice in Italy 
2010 Non-ACS population 
71 Cotter, G. Lack of aspirin effect: Aspirin resistance or resistance to taking 
aspirin? 
2004 Adherence as a 
predictor rather than 
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outcome 
72 Crawford-Faucher, A. Prolonged clopidogrel use after cardiac stenting is not beneficial 2012 Commentary 
73 Cruden, N. L. Delay in Filling First Clopidogrel Prescription After Coronary 
Stenting Is Associated With an Increased Risk of Death and 
Myocardial Infarction 
2014 Adherence as a 
predictor rather than 
outcome 
74 Cuisset, T. Aspirin noncompliance is the major cause of "aspirin resistance" in 
patients undergoing coronary stenting 
2009 Non-psychosocial 
factors only 
75 Cuisset, T. Non-adherence to aspirin in patients undergoing coronary 
stenting: Negative impact of comorbid conditions and implications 
for clinical management 
2011 Non-psychosocial 
factors only 
76 Danchin, N. Impact of free universal medical coverage on medical care and 
outcomes in low-income patients hospitalized for acute myocardial 
infarction: An analysis from the french national health insurance 
system 
2011 Prevalence only, not 
predictors 
77 Danchin, N. Impact of long-term adherence to beta-blocker therapy on survival 
in statin-treated patients after AMI 
2010 Adherence as a 
predictor rather than 
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outcome 
78 Dangas, G. D. Stent thrombosis after primary angioplasty for STEMI in relation to 
non-adherence to dual antiplatelet therapy over time: results of 
the HORIZONS-AMI trial 
2013 Adherence as a 
predictor rather than 
outcome 
79 D'Ascenzo, F. An international collaborative meta-analysis of predictors of 
coronary stent thrombosis including 30 studies, 225,536 patients, 
and 4,203 thromboses 
2011 Review 
80 D'Ascenzo, F. Discontinuation of Dual Antiplatelet Therapy Over 12 Months after 
Acute Coronary Syndromes Increases Risk for Adverse Events in 
Patients Treated with Percutaneous Coronary Intervention: 
Systematic Review and Meta-Analysis 
2014 Review 
81 D'Ascenzo, F. Discontinuation of dual antiplatelet therapy over 12 months after 
acute coronary syndromes increases risk for adverse events in 
patients treated with percutaneous coronary intervention: 
systematic review and meta-analysis 
2014 Duplicate 
82 Daskalopoulou, S. S. Discontinuation of statin therapy following an acute myocardial 2008 Prevalence only, not 
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infarction: a population-based study predictors 
83 Dauerman, H. Thrombosis, bleeding and DAPT non-adherence in the EDUCATE 
registry 
2013 Non-ACS population 
84 Davis, E. M. Impact of prescription refill reminders for clopidogrel therapy in 
patients receiving drug-eluting stents 
2013 Non-psychosocial 
factors only 
85 De Sa, D. D. C. Compliance with dual antiplatelet therapy following percutaneous 
coronary intervention with drug-eluting stents 
2009 Adherence as a 
predictor rather than 
outcome 
86 Degli Esposti, L. Adherence to Statin Treatment and Health Outcomes in an Italian 
Cohort of Newly Treated Patients: Results From an Administrative 
Database Analysis 
2012 Non-ACS population 
87 Deharo, P. Fixed-dose aspirin-clopidogrel combination enhances compliance 
to aspirin after acute coronary syndrome 
2014 Commentary 
88 Donnelly, J. Prevalence of recommended secondary prevention drug therapies 
in patients with coronary artery disease 
2013 Non-ACS population 
89 Droz, C. Use of drugs recommended for secondary prevention following 
acute myocardial infarction after hospital discharge and 6 months 
2011 Non-psychosocial 
factors only 
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thereafter: Results from the eole cohort 
90 Droz-Perroteau, C. Secondary prevention drugs following acute myocardial infarction 
after hospital discharge, 6 and 24 months thereafter: Results from 
the eole cohort 
2011 Duplicate 
91 Duru, O. K. The medicare part D low-income cost subsidy (LICS) and adherence 
to medications for secondary prevention of cardiovascular disease 
2012 Non-psychosocial 
factors only 
92 Eagle, K. A. Adherence to evidence-based therapies after discharge for acute 
coronary syndromes: an ongoing prospective, observational study 
2004 Non-psychosocial 
factors only 
93 Eccleston, D. Are medication compliance and quality of life after percutaneous 
coronary intervention improved by using combination drug 
therapy? 
2014 Non-psychosocial 
factors only 
94 Ernst, F. R. Effect of early clopidogrel discontinuation on rehospitalization in 
acute coronary syndrome: Results from two distinct patient 
populations 
2011 Prevalence only, not 
predictors 
95 Fairley, S. Acute coronary syndromes in patients with prior MI: Secondary 
prevention and outcomes 
2014 Adherence as a 
predictor rather than 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
80 
 
outcome 
96 Fam, J. M. Outcomes and Predictors of 1 year all-cause mortality in patients 
undergoing percutaneous coronary intervention (PCI) in Singapore 
2013 Adherence as a 
predictor rather than 
outcome 
97 Fam, J. M. Outcomes, outpatient costs and adherence to guideline guided 
therapy in SAP, ACS and STEMI patients undergoing Percutaneous 
Coronary Intervention (PCI) 
2012 Adherence to 
guidelines 
98 Fang, G. Prevalent But Moderate Variation Across Small Geographic Regions 
in Patient Nonadherence to Evidence-based Preventive Therapies 
in Older Adults After Acute Myocardial Infarction 
2014 Prevalence only, not 
predictors 
99 Fath-Ordoubadi, F. Gender impact on prognosis of ACS patients treated with DES: 2-
year follow-up 
2012 Non-psychosocial 
factors only 
100 Fennessy, M. M. Changing Illness Perceptions and Adherence to Dual Antiplatelet 
Therapy in Patients With Stable Coronary Disease 
2013 Non-ACS population 
101 Fernandez, R. What do we know about the long term medication adherence in 
patients following percutaneous coronary intervention? 
2007 Non-psychosocial 
factors only 
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102 Ferreira-Gonzalez, I. Background, incidence, and predictors of antiplatelet therapy 
discontinuation during the first year after drug-eluting stent 
implantation 
2010 Non-ACS population 
103 Fosbol, E. L. Persistence of evidence based medications after non-st elevation 
myocardial infarction among patients with medicare part D 
prescription coverage 
2012 Adherence as a 
predictor rather than 
outcome 
104 Gehi, A. K. Self-reported medication adherence and cardiovascular events in 
patients with stable coronary heart disease: The heart and soul 
study 
2007 Non-ACS population 
105 Gencer, B. Discontinuation of recommended therapies one year after an 
acute coronary syndrome: Results from a prospective cohort 
2013 Non-psychosocial 
factors only 
106 Gislason, G. H. Long-term compliance with beta-blockers, angiotensin-converting 
enzyme inhibitors, and statins after acute myocardial infarction 
2006 Non-psychosocial 
factors only 
107 Glynn, R. J. Impact of full coverage for preventive medications after myocardial 
infarction on the time course of adherence 
2012 Non-psychosocial 
factors only 
108 Gordon, W. L. Reliability of patient reported medication adherence after an acute 
coronary syndrome 
2012 Prevalence only, not 
predictors 
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109 Gregor, R. D. Compliance with the discharge medication by patients with acute 
coronary syndromes 
2000 Non-psychosocial 
factors only 
110 Griffiths, B. Self-reported use of evidence-based medicine and smoking 
cessation 6 - 9 months after acute coronary syndrome: a single-
centre perspective 
2014 Prevalence only, not 
predictors 
111 Griffo, R. Effective secondary prevention through cardiac rehabilitation after 
coronary revascularization and predictors of poor adherence to 
lifestyle modification and medication. Results of the ICAROS Survey 
2013 Non-ACS population 
11 Grines, C. L. Prevention of premature discontinuation of dual antiplatelet 
therapy in patients with coronary artery stents 
2007 Review 
113 Gujral, G. Impact of community pharmacist intervention discussing patients' 
beliefs to improve medication adherence 
2014 Intervention - no 
baseline associations 
114 Gupta, M. Adherence to evidence-based medications in South Asian and 
white caucasian patients with coronary heart disease-insight from 
the practice registry 
2013 Non-ACS population 
115 Guthrie, R. M. The effects of postal and telephone reminders on compliance with 
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2006 Non-ACS population 
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2 Benner, J. S. Long-term persistence in use of statin therapy in elderly patients 2002 Non-ACS population 
3 Cottrell, W. Exploring beliefs about heart failure treatment in adherent and 
nonadherent patients: use of the repertory grid technique 
2013 Non-ACS population 
4 Jackevicius, C. A. Adherence With Statin Therapy in Elderly Patients With and 
Without Acute Coronary Syndromes 
2002 Non-psychosocial 
factors only 
5 Kassab, Y. Patients’ adherence to secondary prevention pharmacotherapy 
after acute coronary syndromes 
2013 Non-psychosocial 
factors only 
6 Kronish, I. M. Persistent depression affects adherence to secondary prevention 
behaviors after acute coronary syndromes 
2006 Included 
7 Kuepper-Nybelen, J. Association of long-term adherence to evidence-based 
combination drug therapy after acute myocardial infarction with 
all-cause mortality. A prospective cohort study based on claims 
data 
2012 Non-psychosocial 
factors only 
8 Kulik, A. Adherence to statin therapy in elderly patients after hospitalization 
for coronary revascularization 
2011 Non-ACS population 
9 Lee, W. L. Prevalence and predictors of patient adherence to health 
recommendations after acute coronary syndrome: data for 
2012 Non-psychosocial 
factors only 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
108 
 
targeted interventions? 
10 Mixon, A. S. Characteristics associated with postdischarge medication errors 2014 Non-psychosocial 
factors only 
11 Molloy, G. Practical support predicts medication adherence and attendance at 
cardiac rehabilitation following acute coronary syndrome 
2008 Included 
12 Molloy, G. Social networks and partner stress as predictors of adherence to 
medication, rehabilitation attendance, and quality of life following 
acute coronary syndrome 
2008 Included 
13 Molloy, G. Type D Personality, Self-Efficacy, and Medication Adherence 
Following an Acute Coronary Syndrome 
2012 Included 
14 Molloy, G. Intentional and unintentional non-adherence to medications 
following an acute coronary syndrome: a longitudinal study 
2014 Non-psychosocial 
factors only 
15 Sarkar, U. Self-Efficacy as a Marker of Cardiac Function and Predictor of Heart 
Failure Hospitalization and Mortality in Patients With Stable 
Coronary Heart Disease: Findings From the Heart and Soul Study 
2009 No measure of 
adherence 
16 Stafford, L. Illness Beliefs About Heart Disease and Adherence to Secondary 2008 Non-ACS population 
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Prevention Regimens 
17 Vilchinsky, N. Dynamics of Support Perceptions Among Couples Coping With 
Cardiac Illness: The Effect on Recovery Outcomes 
2011 No measure of 
adherence 
18 Williams, L. Type D personality predicts poor medication adherence in 
myocardial infarction patients 
2011 Included 
19 Zullig, L. Association between perceived life chaos and medication 
adherence in a postmyocardial infarction population 
2013 Included 
 
Appendix II: Full reasons for exclusion table 
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Methodological issue Questions addressed Scoring 
Theoretical background 1. Is a theoretical background presented, to which the 
motivation for conducting the study and/or the hypotheses are 
linked? 
Y = 3, NR = 2, N = 1 
Study participation * 2. Is the study population clearly described in terms of age, 
gender, and important disease characteristics? 
Y = 3, NR = 2, N = 1 
3. Is the percentage of eligible subjects who participated in the 
study (response rate) adequate? 
Y = 3, NR = 1, N = 2 
Sampling 4. Are patients who participated in the study similar to eligible 
non-participants, in terms of age, gender, and important disease 
characteristics? 
Y = 3, NR = 1, N = 2 
Study attrition * 5. Is the percentage of subjects available for analysis adequate 
(i.e.,>70 %)? 
Y = 3, NR = 1, N = 2 
6. Were reasons for loss to follow-up presented and assessed 
during the study for possible systematic attrition? 
Y = 3, NR = 1, N = 2 
Determinant/correlate(s) 
measurement * 
7. Are clear definitions of each determinant and/or correlate 
provided? 
Y = 3, NR = 2, N = 1 
8. Are clear operationalizations of each determinant and/or 
correlate provided? 
Y = 3, NR = 2, N = 1 
9. Are the measurement instruments used for the measurement 
of the determinants and correlates reliable and valid? 
Y = 3, NR = 1, N = 2 
10. Were the measurement approach, time and place of 
measurement of the determinants and/or correlates 
standardized or conducted in a way that limits systematically 
different measurement? 
Y = 3, NR = 2, N = 1 
Outcome variable(s) 
measurement * 
11. Are clear definitions of each outcome variable provided? Y = 3, NR = 2, N = 1 
12. Are clear operationalizations of each outcome variable 
provided? 
Y = 3, NR = 2, N = 1 
13. Are the measurement instruments used for the 
measurement of the outcome variable(s) reliable and valid? 
Y = 3, NR = 2, N = 1 
14. Were the measurement approach, time and place of 
measurement of the outcome variable(s) standardized or 
conducted in a way that limits systematically different 
measurement? 
Y = 3, NR = 2, N = 1 
Statistical analyses * 15. Is the percentage of missing values adequate (i.e.,<30 %)? Y = 3, NR = 1, N = 2 
16. Were multivariable analyses performed? If yes, was it clearly 
described which variables were included in the (multivariable) 
model(s)? 
Y = 3, NR = 1, N = 2 
General limitations 17. Were there any other important flaws in the design or 
analyses of the study? 
Y = 1, NR = 2, N = 3 
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Note. Y = Yes, N = No, NR = Not Reported 
Ratings. Studies that received an average quality score of between 2.5 and 3.0 were regarded as good-quality 
studies, those that received an average score between 2.0 and 2.4 or less were regarded as fair-quality studies, 
and those that received an average score of below 2.0 were regarded as poor-quality studies. 
* One of the 6 QUIPS domains (Study Confounding domain missing - Q16 could be considered to cover 
confounder variables) 
Study Questions Score Rating 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Allen LaPointe [58] 1 3 3 1 3 3 1 1 3 3 3 3 1 3 1 3 3 2.3 Fair 
Castellano [59] 3 3 3 1 3 - 1 1 3 3 3 3 3 3 1 2 3 2.4 Fair 
Jin [60] 3 3 3 3 3 3 3 3 3 3 1 3 1 3 1 2 3 2.6 Good 
Kronish [61] 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 2.9 Good 
Kronish [62] 3 3 1 1 3 1 3 3 3 3 3 3 3 3 1 3 3 2.5 Good 
McGee [63] 3 3 3 3 3 3 3 3 3 1 1 1 1 1 1 2 3 2.2 Fair 
Molloy [64] 3 3 3 3 3 3 3 3 3 3 1 1 1 3 3 3 3 2.6 Good 
Molloy [65] 3 3 3 3 3 1 3 3 2 3 3 3 2 3 3 3 3 2.8 Good 
Molloy [66] 3 3 3 3 3 1 3 3 2 3 3 3 3 3 3 2 3 2.8 Good 
Rieckmann [67] 3 3 3 2 3 3 3 3 3 3 3 3 3 3 1 1 3 2.7 Good 
Rieckmann [68] 3 3 3 2 3 3 3 3 3 3 3 3 3 3 1 2 3 2.8 Good 
Romanelli [69] 3 3 2 1 3 3 3 3 3 3 3 2 2 3 1 1 3 2.5 Good 
Schulman-Marcus [70] 2 2 3 1 1 - 2 2 3 3 2 2 3 3 1 3 1 2.1 Fair 
Shemesh [71] 3 3 3 1 2 3 3 3 1 3 3 3 1 3 1 1 1 2.2 Fair 
Sud [72] 3 3 2 3 3 - 3 3 3 3 3 3 3 3 1 3 3 2.8 Good 
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Appendix III: Full quality assessment table for the included studies 
  
Williams [73] 3 3 3 3 2 1 3 3 3 3 3 3 3 3 3 3 3 2.8 Good 
Zullig [74] 3 3 3 3 3 - 3 3 3 3 3 3 3 3 - 3 3 3.0 Good 
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Appendix IV: Funnel plot showing the potential risk of bias for seven studies 
included in a meta-analysis looking at depression as a predictor of medication 
adherence 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
114 
 
 
Identifying psychosocial predictors of medication non-adherence 
following acute coronary syndrome: a systematic review and meta-
analysis 
 
Highlights 
- A meta-analysis revealed depressed patients were twice as likely to be non-adherent compared 
to non-depressed. 
- There was some evidence that treatment beliefs predicted medication non-adherence. 
- Some psychosocial factors may be targetable for intervention to improve adherence rates. 
